Latest News
Arcutis Biotherapeutics, Inc.
- Arcutis Biotherapeutics, Inc. Estimates – NASDAQ:ARQT
- Form 144 Arcutis Biotherapeutics For: 20 October By Investing.com
- Form 144 Arcutis Biotherapeutics For: 20 October By Investing.com
- Arcutis Biotherapeutics (NASDAQ:ARQT) Looks Undervalued as Growth and Margins Support the Value Case
- Form 4 Arcutis Biotherapeutics Inc: Howard G. Welgus (Director) For: 15 October
- Arcutis Biotherapeutics (ARQT) Shares Rally to 52-Week High Amid Strong Momentum
- Arcutis Biotherapeutics advances 11% to new 52-week high (ARQT:NASDAQ)
- Arcutis Biotherapeutics stock hits 52-week high at $31.80
- Simone Biles reveals how her embarrassing skin condition journey inspired Arcutis Biotherapeutics awarene
- Arcutis' Zoryve sticks the landing with gymnast Simone Biles in new awareness campaign
- Arcutis Biotherapeutics: An Emerging GARP Stock (NASDAQ:ARQT)
- Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade) (NASDAQ:ARQT)
Headlines from the last 30 days, linking to the original publishers. See all market news →